|
If signs and symptoms of tardive dyskinesia appear in a patient treated on RISPERDAL ® , drug discontinuation should be considered. However, some patients may require treatment with RISPERDAL ® despite the presence of the syndrome. Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients With Dementia Cerebrovascular adverse events ( e. g. , stroke, transient schemic attack) , including fatalities, were reported in patients ( mean age 85 years; range 73-97) n trials of risperidone in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher ncidence of cerebrovascular adverse events in patients treated with risperidone compared to patients treated with placebo. RISPERDAL ® is not approved for the treatment of patients with dementia-related psychosis. Hyperglycemia and Diabetes Mellitus Text Continues Below
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including RISPERDAL ® . Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events n patients treated with atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus ( e. g. , obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
